

Androgen receptors beyond prostate cancer: an old marker as a new target

SUPPLEMENTAL REFERENCES

1. Ito FA, Ito K, Coletta RD, *et al.* Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors. *Braz Oral Res* 2009;23(4):393-8.
2. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. *Am J Clin Pathol* 2003;119(6):801-6.
3. Glas AS, Hollema H, Nap RE, *et al.* Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. *Cancer* 2002;94(8):2211-6.
4. Moriki T, Ueta S, Takahashi T, *et al.* Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. *Cancer* 2001;93(5):344-50.
5. Fan CY, Melhem MF, Hosal AS, *et al.* Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. *Arch Otolaryngol Head Neck Surg* 2001;127(9):1075-9.
6. Jaspers HC, Verbist BM, Schoffelen R, *et al.* Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. *J Clin Oncol* 2011;29(16):e473-6.
7. Locati LD, Quattrone P, Bossi P, *et al.* A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. *Ann Oncol* 2003;14(8):1327-8.
8. Kuroda H, Sakurai T, Yamada M, *et al.* [Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma]. *Gan To Kagaku Ryoho* 2011;38(4):627-30.
9. Rajoria S, Suriano R, George A, *et al.* Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer. *PLoS One* 2011;6(1):e15879.
10. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. *Future Oncol* 2010;6(11):1771-9.
11. Negri E, Ron E, Franceschi S, *et al.* A pooled analysis of case-control studies of thyroid cancer. I. Methods. *Cancer Causes Control* 1999;10(2):131-42.
12. Blechet C, Lecomte P, De Calan L, *et al.* Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma. *Virchows Arch* 2007;450(4):433-9.
13. Banu KS, Govindarajulu P, Aruldas MM. Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. *Endocr Pathol* 2001;12(3):315-27.
14. Wiseman SM, Melck A, Masoudi H, *et al.* Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. *Ann Surg Oncol* 2008;15(10):2811-26.
15. Prinz RA, Sandberg L, Chaudhuri PK. Androgen receptors in human thyroid tissue. *Surgery*. 1984 Dec;96(6):996-1000.
16. Lemon HM, Ravin IS, Ross JF, *et al.* Testosterone therapy of metastatic adenocarcinoma of the thyroid, with remission; case report. *Cancer* 1951;4(6):1176-92.
17. Ishibashi H, Suzuki T, Suzuki S, *et al.* Sex steroid hormone receptors in human thymoma. *J Clin Endocrinol Metab* 2003;88(5):2309-17.
18. Mimae T, Tsuta K, Takahashi F, *et al.* Steroid receptor expression in thymomas and thymic carcinomas. *Cancer* 2011;117(19):4396-405.

19. Khoury T, Chandrasekhar R, Wilding G, *et al.* Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma. *Int J Exp Pathol* 2011;92(2):87-96.
20. Chapman MS, Askew DJ, Kuscuoğlu U, *et al.* Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. *Mol Endocrinol* 1996;10(8):967-78.
21. Hagen R, Schweikert HU, Schwab B, *et al.* [Hormone dependence of juvenile nasopharyngeal fibroma]. *Laryngorhinootologie* 1991;70(6):279-83.
22. Brentani MM, Butugan O, Oshima CT, *et al.* Multiple steroid receptors in nasopharyngeal angiofibromas. *Laryngoscope* 1989;99(4):398-401.
23. Hwang HC, Mills SE, Patterson K, *et al.* Expression of androgen receptors in nasopharyngeal angiofibroma: an immunohistochemical study of 24 cases. *Mod Pathol* 1998;11(11):1122-6.
24. Montag AG, Tretiakova M, Richardson M. Steroid hormone receptor expression in nasopharyngeal angiofibromas. Consistent expression of estrogen receptor beta. *Am J Clin Pathol* 2006;125(6):832-7.
25. Gates GA, Rice DH, Koopmann CF, Jr., *et al.* Flutamide-induced regression of angiofibroma. *Laryngoscope* 1992;102(6):641-4.
26. Bianchini C, Pastore A, Pelucchi S, *et al.* Sex hormone receptor levels in laryngeal carcinoma: a comparison between protein and RNA evaluations. *Eur Arch Otorhinolaryngol* 2008;265(9):1089-94.
27. Virolainen E, Vanharanta R, Carey TE. Steroid hormone receptors in human squamous carcinoma cell lines. *Int J Cancer* 1984;33(1):19-25.
28. Mattox DE, Von Hoff DD, McGuire WL. Androgen receptors and antiandrogen therapy for laryngeal carcinoma. *Arch Otolaryngol* 1984;110(11):721-4.
29. Kokoschka EM, Spona J, Knobler R. Sex steroid hormone receptor analysis in malignant melanoma. *Br J Dermatol* 1982;107 Suppl 23:54-9.
30. Gershtein ES, Tailakov BB, Smirnova KD, *et al.* [Cytoplasmic receptors of steroid hormones and clinico-morphological characteristics of skin melanoma]. *Vopr Onkol* 1991;37(4):441-6.
31. Morvillo V, Luthy IA, Bravo AI, *et al.* Atypical androgen receptor in the human melanoma cell line IIB-MEL-J. *Pigment Cell Res* 1995;8(3):135-41.
32. Morvillo V, Luthy IA, Bravo AI, *et al.* Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases. *Melanoma Res* 2002;12(6):529-38.
33. Nardone PA, Slotman GJ, Vezeridis MP. Ketoconazole: a thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma. *J Surg Res* 1988;44(4):425-9.
34. Katona TM, Perkins SM, Billings SD. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? *J Cutan Pathol* 2008;35(2):174-9.
35. Izikson L, Bhan A, Zembowicz A. Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. *Am J Dermatopathol* 2005;27(2):91-5.
36. Dohi O, Hatori M, Suzuki T, *et al.* Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. *Cancer Sci* 2008;99(3):518-23.
37. Liu J, Chen X, Li S, *et al.* [Expression and significance of AR in osteosarcoma]. *Zhonghua Wai Ke Za Zhi* 2000;38(5):344-5, 23.
38. Lin KL, Huang CC, Cheng JS, *et al.* Ketoconazole-induced JNK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. *Toxicol In Vitro* 2009;23(7):1268-76.
39. Brodsky SV, Gimenez C, Ghosh C, *et al.* Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointestinal leiomyomas. *Int J Gastrointest Cancer* 2006;37(4):129-32.
40. Lam MM, Corless CL, Goldblum JR, *et al.* Extragastrintestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. *Int J Gynecol Pathol* 2006;25(3):288-92.
41. Walker MJ, Chaudhuri PK, Beattie CW, *et al.* Steroid receptors in malignant skeletal tumors. *Cancer* 1980;45(12):3004-7.

42. Ziegler JL, Katongole-Mbidde E, Wabinga H, *et al.* Absence of sex-hormone receptors in Kaposi's sarcoma. *Lancet* 1995;345(8954):925.
43. Pais V, Leav I, Lau KM, *et al.* Estrogen receptor-beta expression in human testicular germ cell tumors. *Clin Cancer Res* 2003;9(12):4475-82.
44. Rajpert-De Meyts E, Skakkebaek NE. Immunohistochemical identification of androgen receptors in germ cell neoplasia. *J Endocrinol* 1992;135(2):R1-4.
45. Langner C, Ratschek M, Rehak P, *et al.* Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. *J Urol* 2004;171(2 Pt 1):611-4.
46. Brown DF, Dababo MA, Hladik CL, *et al.* Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas. *Mod Pathol* 1998;11(1):55-9.
47. Klotzl G, Otto U, Becker H, *et al.* Determination of androgen, progestin and estrogen receptors with two different assays in renal cell carcinoma. *Urol Int* 1987;42(2):100-4.
48. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. *J Clin Oncol* 2009;27(27):4619-29.
49. Barzon L, Masi G, Pacenti M, *et al.* Expression of aromatase and estrogen receptors in human adrenocortical tumors. *Virchows Arch* 2008;452(2):181-91.
50. Rossi R, Zatelli MC, Valentini A, *et al.* Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. *J Endocrinol* 1998;159(3):373-80.
51. Harinarayan CV, Gupta S, Ammini AC, *et al.* Clinical utility of ketoconazole in cases of adrenocortical carcinoma. *Indian J Cancer* 1991;28(4):196-201.
52. Verhelst JA, Druwe P, van Erps P, *et al.* Use of ketoconazole in the treatment of a virilizing adrenocortical carcinoma. *Acta Endocrinol (Copenh)* 1989;121(2):229-34.
53. Mir C, Shariat SF, van der Kwast TH, *et al.* Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU Int* 2011;108(1):24-30.
54. Miyamoto H, Yao JL, Chaux A, *et al.* Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. *BJU Int* 2012;109(11):1716-26.
55. Tuygun C, Kankaya D, Imamoglu A, *et al.* Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. *Urol Oncol* 2011;29(1):43-51.
56. Miyamoto H, Yang Z, Chen YT, *et al.* Promotion of bladder cancer development and progression by androgen receptor signals. *J Natl Cancer Inst* 2007;99(7):558-68.
57. Hameed DA, el-Metwally TH. The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. *Cancer Biol Ther* 2008;7(1):92-100.
58. Leav I, Lau KM, Adams JY, *et al.* Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. *Am J Pathol* 2001;159(1):79-92.
59. Gustafsson JA, Ekman P, Snochowski M, *et al.* Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer. *Cancer Res* 1978;38(11 Pt 2):4345-8.
60. Ekman P, Gustafsson JA, Hogberg B, *et al.* Prediction of tumor response to endocrine therapy in prostatic carcinoma based on steroid receptor assay. *Scand J Urol Nephrol Suppl* 1980;55:83-9.
61. Bassalyk LS, Petrova AS, Ermilova VD, *et al.* [Relationship between androgen and estrogen receptors and clinico-morphological characteristics of prostatic cancer]. *Arkh Patol* 1983;45(2):23-8.
62. Kaiser U, Hofmann J, Schilli M, *et al.* Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. *Int J Cancer* 1996;67(3):357-64.
63. Rades D, Setter C, Dahl O, *et al.* The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. *Cancer* 2012;118(1):157-63.

64. Maasberg M, Rotsch M, Jaques G, *et al.* Androgen receptors, androgen-dependent proliferation, and 5 alpha-reductase activity of small-cell lung cancer cell lines. *Int J Cancer* 1989;43(4):685-91.
65. Wu CW, Chi CW, Chang TJ, *et al.* Sex hormone receptors in gastric cancer. *Cancer* 1990;65(6):1396-400.
66. Kominea A, Konstantinopoulos PA, Kapranos N, *et al.* Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. *J Cancer Res Clin Oncol* 2004;130(5):253-8.
67. Nakamura Y, Shimada N, Suzuki T, *et al.* In situ androgen production in human gastric carcinoma--androgen synthesizing and metabolizing enzymes. *Anticancer Res* 2006;26(3A):1935-9.
68. Yamashita Y, Hirai T, Mukaida H, *et al.* Detection of androgen receptors in human esophageal cancer. *Jpn J Surg* 1989;19(2):195-202.
69. Tihan T, Harmon JW, Wan X, *et al.* Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus. *Anticancer Res* 2001;21(4B):3107-14.
70. Cooper SC, Trudgill NJ. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database. *Cancer Causes Control* 2012;23(6):819-25.
71. Corbishley TP, Iqbal MJ, Wilkinson ML, *et al.* Androgen receptor in human normal and malignant pancreatic tissue and cell lines. *Cancer* 1986;57(10):1992-5.
72. Targarona EM, Pons MD, Gonzalez G, *et al.* Is exocrine pancreatic cancer a hormone-dependent tumor? A study of the existence of sex hormone receptors in normal and neoplastic pancreas. *Hepatogastroenterology* 1991;38(2):165-9.
73. Sharma JJ, Razvillas B, Stephens CD, *et al.* Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. *Invest New Drugs* 1997;15(4):361-4.
74. Greenway BA. Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial. *BMJ* 1998;316(7149):1935-8.
75. Andren-Sandberg A, Hoem D, Backman PL. Other risk factors for pancreatic cancer: hormonal aspects. *Ann Oncol* 1999;10 Suppl 4:131-5.
76. Konduri S, Schwarz MA, Cafasso D, *et al.* Androgen receptor blockade in experimental combination therapy of pancreatic cancer. *J Surg Res* 2007;142(2):378-86.
77. Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. *J Urol* 2011;185(1):17-23.
78. Sun M, Estrov Z, Ji Y, *et al.* Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. *Mol Cancer Ther* 2008;7(3):464-73.
79. Tutton PJ, Barkla DH. The influence of androgens, anti-androgens, and castration on cell proliferation in the jejunal and colonic crypt epithelia, and in dimethylhydrazine-induced adenocarcinoma of rat colon. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1982;38(3):351-5.
80. Stebbings WS, Farthing MJ, Vinson GP, *et al.* Androgen receptors in rectal and colonic cancer. *Dis Colon Rectum* 1986;29(2):95-8.
81. Meggouh F, Lointier P, Pezet D, *et al.* Status of sex steroid hormone receptors in large bowel cancer. *Cancer* 1991;67(7):1964-70.
82. Berta L, Fronticelli Baldelli C, Fazzari A, *et al.* Sex steroid receptors, secondary bile acids and colorectal cancer. A possible mechanism of interaction. *Panminerva Med* 2003;45(4):261-6.
83. Castagnetta L, Traina A, Campisi I, *et al.* Androgen receptor status in nontumoral and malignant human colorectal tissues. *Ann N Y Acad Sci* 2002;963:322-5.
84. Forgue-Lafitte ME, Coudray AM, Fagot D, *et al.* Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines. *Cancer Res* 1992;52(24):6827-31.
85. Ishizuka M, Hatori M, Dohi O, *et al.* Expression profiles of sex steroid receptors in desmoid tumors. *Tohoku J Exp Med* 2006;210(3):189-98.
86. van Dam JH, Schouten WR, Kok TC. [Treatment and course of desmoid tumors in 5 patients with familial adenomatous polyposis]. *Ned Tijdschr Geneesk* 1993;137(14):716-20.
87. Bauernhofer T, Stoger H, Schmid M, *et al.* Sequential treatment of recurrent mesenteric desmoid tumor. *Cancer* 1996;77(6):1061-5.

88. Merritt RL, Foran CM. Influence of persistent contaminants and steroid hormones on glioblastoma cell growth. *J Toxicol Environ Health A* 2007;70(1):19-27.
89. Chung YG, Kim HK, Lee HK, *et al.* Expression of androgen receptors in astrocytoma. *J Korean Med Sci* 1996;11(6):517-21.
90. Lee LS, Chi CW, Chang TJ, *et al.* Steroid hormone receptors in meningiomas of Chinese patients. *Neurosurgery* 1989;25(4):541-5.
91. Noel JC, Bucella D, Fayt I, *et al.* Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. *Int J Gynecol Pathol* 2008;27(3):437-41.
92. Yang HP, Gonzalez Bosquet J, Li Q, *et al.* Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. *Carcinogenesis* 2010;31(5):827-33.
93. Ito K, Suzuki T, Akahira J, *et al.* Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. *Int J Cancer* 2002;99(5):652-7.
94. Brys M, Semczuk A, Baranowski W, *et al.* Androgen receptor (AR) expression in normal and cancerous human endometrial tissues detected by RT-PCR and immunohistochemistry. *Anticancer Res* 2002;22(2A):1025-31.
95. Koivisto-Korander R, Butzow R, Koivisto AM, *et al.* Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. *Tumour Biol* 2011;32(3):451-9.
96. Moinfar F, Regitnig P, Tabrizi AD, *et al.* Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. *Virchows Arch* 2004;444(5):410-4.
97. Leitao MM, Soslow RA, Nonaka D, *et al.* Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. *Cancer* 2004;101(6):1455-62.
98. al-Timimi A, Buckley CH, Fox H. An immunohistochemical study of the incidence and significance of sex steroid hormone binding sites in normal and neoplastic human ovarian tissue. *Int J Gynecol Pathol* 1985;4(1):24-41.
99. Elattar A, Warburton KG, Mukhopadhyay A, *et al.* Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. *Gynecol Oncol* 2012;124(1):142-7.
100. Jones MW, Harri R, Dabbs DJ, *et al.* Immunohistochemical profile of steroid cell tumor of the ovary: a study of 14 cases and a review of the literature. *Int J Gynecol Pathol* 2010;29(4):315-20.
101. Nodin B, Zendehtrokh N, Brandstedt J, *et al.* Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. *J Ovarian Res* 2010;3:14.
102. Dizon DS, Tejada-Berges T, Koelliker S, *et al.* Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. *Gynecol Obstet Invest* 2006;62(4):226-8.
103. Levine D, Park K, Juretzka M, *et al.* A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. *Cancer* 2007;110(11):2448-56.
104. Wang PH, Chang C. Androgens and ovarian cancers. *Eur J Gynaecol Oncol* 2004;25(2):157-63.
105. van Doorn HC, Burger CW, van der Valk P, *et al.* Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. *J Clin Pathol* 2000;53(3):201-5.
106. Tumolo S, Rao BR, van der Burg ME, *et al.* Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. *Eur J Cancer* 1994;30A(7):911-4.
107. Klotz RK, Muller-Holzner E, Fessler S, *et al.* Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. *Exp Clin Endocrinol Diabetes* 2010;118(5):291-7.
108. Papadatos-Pastos D, Dedes KJ, de Bono JS, *et al.* Revisiting the role of antiandrogen strategies in ovarian cancer. *Oncologist* 2011;16(10):1413-21.

109. Peters KM, Edwards SL, Nair SS, *et al.* Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. *BMC Cancer* 2012;12:132.
110. Lin Fde M, Pincerato KM, Bacchi CE, *et al.* Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity. *J Clin Pathol* 2012;65(1):64-8.
111. Hu R, Dawood S, Holmes MD, *et al.* Androgen receptor expression and breast cancer survival in postmenopausal women. *Clin Cancer Res* 2011;17(7):1867-74.
112. Pristaux G, Petru E, Stacher E, *et al.* Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. *Histopathology* 2010;57(6):877-84.
113. Qi JP, Yang YL, Zhu H, *et al.* Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. *Breast Cancer (Auckl)* 2012;6:1-8.
114. Cimino-Mathews A, Hicks JL, Illei PB, *et al.* Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. *Hum Pathol* 2012;43(7):1003-11.
115. Collins LC, Cole KS, Marotti JD, *et al.* Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. *Mod Pathol* 2011;24(7):924-31.
116. Lehmann BD, Bauer JA, Chen X, *et al.* Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest* 2011;121(7):2750-67.
117. Doane AS, Danso M, Lal P, *et al.* An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. *Oncogene* 2006;25(28):3994-4008.
118. De Amicis F, Thirugnansampanthan J, Cui Y, *et al.* Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. *Breast Cancer Res Treat* 2010;121(1):1-11.
119. Gucalp A, Tolaney SM, Isakoff SJ, *et al.* Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). *J Clin Oncol* 2012;30(Suppl_2):1006.